ORIC · CIK 0001796280
Oric Pharmaceuticals, Inc.
What Oric Pharmaceuticals, Inc. owns has not been researched yet. This page is its ownership register, who holds it, and the absence of holdings below means nobody has looked rather than that there is nothing to find.
Oric Pharmaceuticals, Inc. - Profile
- Industry
- Pharmaceutical PreparationsSIC 2834
- Listed on
- Nasdaq
- Employees
- 104stated 2025
- Incorporated in
- Delaware
- Financial year ends
- 31 December
Source
Address, industry classification, listing and incorporation come from Oric Pharmaceuticals, Inc.'s own SEC filer record, so the industry is the SEC's dry classification rather than a marketing label. The headcount is the figure the sources below state for 2025. The description was written for this site in August 2026 from ORIC Pharmaceuticals, Inc. Form 10-K for fiscal year 2025, ORIC Pharmaceuticals, Inc. Form 8-K dated 3 August 2026, Exhibit 99.1 (second quarter 2026 results) and ORIC Pharmaceuticals, Inc. Form 10-Q for the quarter ended 30 June 2026, not taken from any single article.
Share price
ORIC
Description
ORIC Pharmaceuticals, Inc. is a clinical stage oncology company in South San Francisco and San Diego, California, whose name stands for Overcoming Resistance In Cancer and whose two candidates both attack mechanisms of therapeutic resistance. Rinzimetostat (formerly ORIC-944), an allosteric PRC2 inhibitor acting via the EED subunit and licensed from Mirati Therapeutics, entered the global Phase 3 Himalayas-1 registrational trial in July 2026 in post-abiraterone metastatic castration-resistant prostate cancer: about 600 patients across 25 countries, randomized against physician's choice, primary endpoint radiographic progression-free survival. Bayer supplies its androgen receptor inhibitor darolutamide free of charge for that trial without taking any rights to rinzimetostat. Enozertinib (formerly ORIC-114), a brain-penetrant inhibitor of EGFR exon 20 insertion and atypical mutations licensed from Voronoi Inc., is in first-line Phase 1b trials in non-small cell lung cancer, with monotherapy data due at ESMO in October 2026. An August 2025 pipeline prioritization eliminated the discovery research group and about 20% of staff. Net loss was $129.5 million in 2025 and $77.3 million in the first half of 2026, with no product revenue to date. Cash, cash equivalents and investments were $387.6 million at 30 June 2026, expected to fund the operating plan into the second half of 2028.
Who owns Oric Pharmaceuticals, Inc..
Nothing recorded on this side. That is a sourced finding rather than a gap where the research notes say so: see the notes below.
Select a row or a slice for its provenance: the filing it came from, when it was measured, and the arithmetic behind it if it was modelled.
The full register, from 13F filings
The Register tab above is hand research: a dozen holders, each traced to the filing it came from. This asks the same question of the whole market for the quarter ended 31-mar-2026, where 177 managers reported a position. Broad where the research is deep, and shallow in the ways a 13F always is.
177 managers reported a position, together holding 119.4m shares, or 115.3% of the company. The 40 largest are listed. Percentages are of the 103.5m shares outstanding at 27 Apr 2026, the count in force when this quarter was measured rather than the count today.
This adds up to more than the whole company, and that is what the filings say. A 13F total can exceed 100% because the same share can be reported twice: when a holder lends stock, the borrower sells it to someone else, and both the lender's manager and the new buyer's manager report it. The gap tracks how heavily a stock is shorted. It is a property of 13F rather than a fault in this data, so it is shown as filed, and it cannot be used as evidence that a particular holder's stake is large.
Built from 13F filings, which report US listed, long, US custodied positions only. A register from this source is a floor rather than a level: a holder's true position can be far larger, as BlackRock's ASML stake shows at 1.28m shares in a 13F against 26.3m in its 13G/A. Holdings held through derivatives, outside US custody, or below a manager's reporting obligation do not appear. Where a holder is marked as a family, its total sums several separate filing entities and describes something no single filing describes; the constituent entities and their share counts are listed so the total can be checked. That roll-up can legitimately exceed the family's own Schedule 13G, because a 13G is filed by one legal entity: Vanguard reports Alphabet through ten advisory entities, and The Vanguard Group Inc itself reported zero after its January 2026 disaggregation.
What a reader needs to know to read these numbers
- Added 27 Aug 2026 by scripts/promote_discovered.py. This company reached the site because a covered investor holds it, not because an index listed it: it was a position in a portfolio here with no page of its own. The match was proved by requiring the register built for this CIK to contain the same CUSIP the portfolio held.
- Discovered at CUSIP 68622P109, held by allstate, bank-of-america, blackrock, bny-mellon, citigroup, fidelity-fmr, franklin-resources, geode, goldman-sachs, invesco, jpmorgan, metlife, morgan-stanley, northern-trust, pfizer, prudential-financial, state-street, vanguard, wells-fargo.
- Holdings are NOT researched. The empty holdings list means nobody has looked at what this company owns, not that it owns nothing, and the page says so.
- Shares outstanding and market cap are null rather than guessed. Neither was captured on the dated sweep that carries every other company here.
Looked for, not found
Recorded rather than filled in. Each of these is a place where a number could have been invented and was not.
- Shares outstanding.
- Market capitalisation.